Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 11/20 | 1.00 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.49 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13932867 | 0.85 | STS (0.74) | STSTGFBR1SFRP1EPHX2 | |
| SCHEMBL2921990 | 0.82 | STS (0.70) | STSTGFBR1TACR1 | |
| SCHEMBL22089514 | 0.78 | STS (0.77) | STSTGFBR1PTPN2PTPN1PTPN6 | |
| SCHEMBL22503103 | 0.77 | STS (0.62) | STSPTPN2PTPN1PTPN6EPHX2 | |
| SCHEMBL2925179 | 0.77 | STS (0.62) | STSEPHX2TACR1 | |
| SCHEMBL2920158 | 0.77 | STS (0.62) | STSTGFBR1SFRP1TACR1 | |
| SCHEMBL15555181 | 0.76 | STS (0.62) | STSTGFBR1PTPN2PTPN1PTPN6 | |
| SCHEMBL4725927 | 0.76 | SFRP1 (0.77) | STSSFRP1 | |
| Tert-Butyl Formate SCHEMBL27590706 | 0.76 | STS (0.61) | STSSFRP1EPHX2TACR1 | |
| SCHEMBL16895185 | 0.76 | PTPN2 (0.61) | STSPTPN2PTPN1PTPN6EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2228364-A1 | Acylsulfonamides as inhibitors of steroid sulfatase | Novartis AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | MEINGASSNER JOSEF GOTTFRIED | 2009-09-10 | — | — | US | disclosed |
| US-7482462-B2 | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2009-01-27 | — | — | US | disclosed |
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| EP-1861098-A1 | ANTI-INFLAMMATORY COMPOUNDS | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| EP-1861099-A2 | COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097293-A2 | COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006097292-A1 | ANTI-INFLAMMATORY COMPOUNDS | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| EP-1436253-A1 | ACYLSULFONAMIDES AS INHIBITORS OF STEROID SULFATASE | Novartis AG (CH) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003031397-A1 | ACYLSULFONAMIDES AS INHIBITORS OF STEROID SULFATASE | NOVARTIS AG (CH) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | STS, ARSA, CYP17A1 | STS 1/4885TGFBR1 4342/4885PTPN2 1898/4885 |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | STS, SERPINB1, MPO | STS 1/4885TGFBR1 4038/4885PTPN2 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.